FDA SSED (Summary of Safety and Effectiveness Data)

A Summary of Safety and Effectiveness Data (SSED) is a comprehensive regulatory review document prepared by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). Released publicly after an approval order is issued for an original Premarket Approval (PMA) application or a panel-track supplement, the SSED documents the scientific and clinical evidence that supports marketing authorization for Class III medical devices.

In accordance with regulatory transparency requirements, the SSED synthesizes both positive and negative evidence submitted by the device sponsor, detailing how the FDA concluded that there is a reasonable assurance of safety and effectiveness for the device’s specified indications for use. Understanding the structure and data requirements of an SSED is essential for clinical researchers, trial biostatisticians, and biomedical device engineers designing investigational protocols or navigating premarket pathways under what is a medical device framework.

Statutory Authority and Regulatory Mandate

The requirement to generate and publish an SSED stems directly from federal statute and FDA regulations governing Class III medical devices:

• FD&C Act Section 520(h)(1)(A): Under 21 U.S.C. § 360j(h)(1)(A), the FDA is legally required to make publicly available a detailed summary of safety and effectiveness data for any approved original PMA application or panel-track PMA supplement.
• 21 CFR § 814.44(d): Within 21 CFR Part 814 (Premarket Approval of Medical Devices), this provision mandates that upon issuing an approval order, the agency must place on public display a detailed summary of the information respecting safety and effectiveness that formed the basis for approval.
• 21 CFR § 814.9: Defines public disclosure rules, protecting trade secrets and confidential commercial manufacturing methods while ensuring that scientific findings, trial results, and safety profiles are disclosed.

Unlike a 510(k) summary—which demonstrates substantial equivalence to a legally marketed predicate device under Class II pathways—an SSED reflects an independent demonstration of safety and effectiveness based on valid scientific evidence under FDA medical device regulations.

Standard Sections of an FDA SSED

An SSED follows a rigorous, uniform format designed to provide regulatory assessors, healthcare practitioners, and research scientists with a clear audit trail of the agency’s evaluation. The key components include:

SSED Section	Core Contents and Data Requirements	Regulatory Focus
General Information	Device trade and generic names, applicant identity, PMA number, and approval date.	Administrative identification and regulatory tracking.
Indications for Use & Contraindications	Target clinical population, specific diseases or conditions, anatomical sites, and conditions where device use is prohibited.	Approved clinical scope and patient safety boundaries.
Device Description	Physical construction, mechanism of action, software architecture, materials, and sterile barrier details.	Engineering specifications and operational mechanics.
Non-Clinical Laboratory Studies	Biocompatibility assays (ISO 10993), bench durability and fatigue testing, electrical safety/EMC, animal models, sterility assurance, and packaging shelf-life.	Preclinical validation of physical and biological integrity.
Clinical Investigations	Study design (prospective, randomized, controlled), primary and secondary safety/effectiveness endpoints, sample size justification, patient demographics, accountability, and adverse events.	Pivotal human trial data evaluating clinical performance.
CDRH Benefit-Risk Determination	Integrated assessment balancing probable health benefits against probable risks and complications under 21 CFR § 860.7.	Final regulatory rationale for market approval order.

Research and Practice Utility in Medical Device Development

For clinical researchers, regulatory strategists, and academic investigators, the SSED functions as one of the most transparent primary resources in translational medicine:

• Benchmarking Trial Endpoints: Investigational Device Exemption (IDE) teams analyze published SSEDs to identify validated primary endpoints, acceptable margin sizes for non-inferiority trials, and expected drop-out rates in specific patient cohorts.
• Adverse Event Baselining: The granular safety tables in an SSED report all adverse events, device-related complications, and secondary surgical interventions observed during pivotal studies, providing essential background safety rates for protocol risk analyses.
• Preclinical Test Battery Design: Reviewing the non-clinical section illuminates the exact bench test regimens (e.g., accelerated aging cycles, cyclic fatigue thresholds, computational modeling simulations) requested by CDRH review divisions for a given device class.
• PMA Database Retrieval: SSED documents are cataloged and searchable in the public PMA database maintained by CDRH, where they can be queried by PMA number, device generic name, or applicant organization.

Sources

• U.S. Food and Drug Administration. Premarket Approval (PMA) Review Process. FDA.gov (read 2026-11-07). https://www.fda.gov/medical-devices/premarket-approval-pma/pma-review-process
• U.S. Food and Drug Administration. Premarket Approval (PMA) Database. Accessdata.fda.gov (read 2026-11-07). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm
• Electronic Code of Federal Regulations. Title 21, Part 814 — Premarket Approval of Medical Devices (21 CFR § 814.20, § 814.44, § 814.9). eCFR.gov (read 2026-11-07). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-814
• United States Code. Title 21, Section 360j — General provisions respecting control of devices intended for humans (FD&C Act Section 520(h)). Office of the Law Revision Counsel (read 2026-11-07). https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360j&num=0&edition=prelim